Squibb is proposing to invest Rs.800 cr creating 1,500 jobs
The new centre would further expand its worldwide presence and draw on the vibrant scientific and technology talent in the region
HYDERABAD: Bristol Myers Squibb, one of the world’s leading biopharmaceutical companies to establish a state-of-the-art site in Hyderabad, India, to expand their global drug development and Information Technology(IT) capabilities.
The company intends to commence operations in Hyderabad later in 2023, with the potential to employ about 1,500 employees in Hyderabad over the next few years in cutting-edge R&D and digital activities.
The BMS Hyderabad facility would help them pursue therapies at the cutting edge of scientific discovery, with the goal of introducing an exciting new generation of life-changing drugs to patients. Specifically, the new centre would further expand its worldwide presence and draw on the vibrant scientific and technology talent in the region.
The announcement came following a meeting between Minister KT Rama Rao and Dr. Samit Hirawat MD, Executive Vice President, Chief Medical Officer, Global Drug Development at BMS, who is in Hyderabad for the 20th edition of the annual international conference BioAsia 2023.
Jayesh Ranjan IAS, Principal Secretary, and Shakthi M. Nagappan, CEO, Telangana Life Sciences, were also present at the meeting.
Speaking after the meeting, Industries and IT Minister K.T.Rama Rao said, “I am delighted to welcome Bristol-Myers Squibb to the vibrant ecosystem of Hyderabad. It is indeed a matter of pride that BMS, which is one of the most innovative and world leading biopharmaceutical company, has chosen Hyderabad and I strongly believe this partnership with BMS is a strategic one. I am confident that the center will engage in cutting-edge R&D and digital work and will provide a great opportunity for our extraordinary talent pool to engage in some highly impactful work.”
Samit Hirawat, M.D., Chief Medical Officer, Global Drug Development, Bristol Myers Squibb, said, “The Hyderabad site is a long-term strategic investment for BMS and we look forward to commencing operations later this year. We are excited about the opportunity to diversify our company globally, which will position us to further accelerate our drug development, bolster our digital innovation capabilities, and advance BMS’s mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our new BMS site in Hyderabad will also create significant employment and economic opportunities locally as we continue to grow our presence in the years ahead".